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Staying at the crossroads: assessment of the 
potential of serum lithium monitoring in predicting 
an ideal lithium dose
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Abstract
Objective: Lithium has been successfully employed to treat bipolar disorder for decades, and recently, was shown to attenuate the 
symptoms of other pathologies such as Alzheimer’s disease, Down’s syndrome, ischemic processes, and glutamate-mediated excitotoxicity. 
However, lithium’s narrow therapeutic range limits its broader use. Therefore, the development of methods to better predict its dose 
becomes essential to an ideal therapy. Method: the performance of adult Wistar rats was evaluated at the open field and elevated plus 
maze after a six weeks treatment with chow supplemented with 0.255%, or 0.383% of lithium chloride, or normal feed. Thereafter, blood 
samples were collected to measure the serum lithium concentration. Results: Animals fed with 0.255% lithium chloride supplemented 
chow presented a higher rearing frequency at the open field, and higher frequency of arms entrance at the elevated plus maze than 
animals fed with a 50% higher lithium dose presented. Nevertheless, both groups presented similar lithium plasmatic concentration. 
Discussion: different behaviors induced by both lithium doses suggest that these animals had different lithium distribution in their 
brains that was not detected by lithium serum measurement. Conclusion: serum lithium concentration measurements do not seem to 
provide sufficient precision to support its use as predictive of behaviors.
Descriptors: Lithium chloride; Brain, lithium levels; Test, anxiety; Open field test; Serum, lithium levels
Resumo
Objetivo: Além de ser usado há décadas para tratar distúrbio bipolar, o lítio, mais recentemente, demonstrou-se eficaz para Alzheimer, 
síndrome de Down, processos isquêmicos e excitotoxicidade mediada por glutamato. Contudo, a estreita janela terapêutica do lítio limita 
seu uso. Portanto, o estabelecimento de métodos preditivos de dose torna-se importante. Método: O desempenho de ratos Wistar adultos 
foi avaliado no campo aberto e labirinto em cruz elevado após seis semanas de tratamento com uma ração suplementada com 0,255% 
ou 0,383% de cloreto de lítio ou ração normal. Coletou-se amostras de sangue para dosagem plasmática do lítio. Resultados: Os ani-
mais alimentados com a ração com 0,255% de cloreto de lítio fizeram mais rearing no campo aberto e tiveram uma maior freqüência 
de entradas nos braços do labirinto elevado que os animais que ingeriram a dose mais alta. Apesar disso, verificou-se níveis plasmáti-
cos de lítio semelhantes em ambos os grupos. Discussão: A variação nos comportamentos destarte a presença de níveis plasmáticos 
semelhantes sugere que as diferentes doses produziram diferentes concentrações cerebrais não detectadas pela medida plasmática. 
Conclusão: Medidas da concentração plasmática de lítio não permitem prever de forma completa seus efeitos comportamentais.
Descritores: Cloreto de lítio; Cérebro, níveis de lítio; Teste, ansiedade; Teste, campo aberto; Soro, níveis de lítio
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Introduction
Since its original proposal as a therapeutic means for the treatment 
of gout in 1817 and its more recent use in psychiatric patients in 
1949 a long clinical experience has been developed with the use 
of lithium chloride. Yet, even for a compound used over such a 
long time there are still reports reminding of or describing for the 
first time aspects associated with its clinical use in neuropsychiatric 
patients.1,2 Recently, It was reported that children may be more 
susceptible to the consequences of overestimation of lithium 
dose, as lithium levels reach a steady-state balance faster in 
youths, leading to earlier toxicity.3 In addition, it was pointed that 
a delayed and slower equilibrium between lithium concentration 
at extracellular space and the inner compartment could result 
in delayed cardiac lithium poisoning.1 These recent discoveries 
highlight that there are a number of features on the clinical use of 
lithium that are yet to be revealed. 
Lithium salts have been successfully used to treat especially the 
classical bipolar disorder.4-7 In spite of this, the narrow therapeutic 
range for the safe use of lithium induces physicians to avoid 
prescribing it, resulting in reduced consumption times of lithium salts. 
Conversely, as new studies demonstrate an increasing potential for 
the treatment of other pathologies the interest in using lithium salts 
was rekindled, being in vogue again. Recently, the use of lithium has 
been proven beneficial over animal models of Alzheimer’s disease, 
Down’s syndrome,8 lesions produced by ischemic processes and 
glutamate-mediated excitotoxicity,9,10 in patients affected by Canavan 
disease,11 and in subjects with a high risk to develop psychosis.12 
Moreover, lithium seems to protect neurons13 and stimulate the 
proliferation and migration of neural stems cells.12,14,15 This current 
expanding use of lithium resumes a need for methods able  to monitor 
the lithium levels, in order to adjust its dosage to reach therapeutic 
effects, besides avoiding its toxicity.
Lithium’s therapeutic window for human clinical use is between: 
0.6 to 1.2 mMol/L serum levels. Thus lithium plasmatic levels 
below the minimum limit result in a higher than acceptable relapse 
risk of manic-depressive symptoms, while serum levels above the 
maximal limit produce intoxication.16,17 Although the security range 
has been established, this does not exclude the occasional toxic 
consequences of lithium. Neurological features may be encountered 
early, including drowsiness, slurred speech, psychomotor slowing, 
and impaired memory and, in severe cases, seizures, coma and 
death.18 Given that lithium is exclusively eliminated by kidneys, 
its therapy is associated with a progressive decline in creatinine 
clearance and an estimated interval of 20 years until end-stage 
renal failure.19,20
The toxicity of lithium is related to its distribution, which is 
determined, mainly, by passive diffusion modulated by bicarbonate. 
Lithium can be also transported by ionic pumps with ATP 
consumption, and through channels coupled to the Na+ driving force 
that in turn is maintained by the associated Na+/K+ pump.21 The 
active transport of lithium allows its concentration at specific systems 
and organs of the body, such as central nervous system (CNS) and 
muscles.22 Actually, lithium levels vary even in the CNS, where 
there is a higher concentration in the brain than in the spinal cord,23 
and the lithium distribution through brain structures may also vary 
according to the administered doses.24 In this way, measurements of 
lithium in a system may not necessarily predict its levels in another 
one. Therefore, this work aimed at evaluating the accuracy and 
relevance of the plasmatic lithium measurement aiming to estimate 
CNS levels in well-controlled laboratory conditions. 
Method
Three-month-old Wistar rats, of both genders, were housed under 
standard laboratory conditions with light/dark cycle (12/12h), lights 
on at 7:00 AM, and food and water were provided ad libitum. All 
experimental protocols were approved by the Animal Care and Use 
Ethics Committee of Universidade Federal de São Paulo. Animals 
were distributed to experimental groups according to the different 
treatments over a period of six weeks. Thus, animals fed with 
conventional rat chow (Nuvilab, Brazil) constituted the control 
group (n = 10); animals that received a 0.255% rich lithium 
chloride (LiCl) rat chow constituted the 0.255 group (n = 8); 
and finally, group 0.383 was composed by 8 animals fed with a 
0.383% LiCl rich feed. The 0.255% lithium supplemented feed 
has already been demonstrated to result in a plasmatic level within 
the therapeutic ranges.25 Here we chose to compare the plasmatic 
levels and the behavioral effect of this dose with a 50% higher 
dose (0.383%). The body weight of all animals was evaluated over 
the six-week period. At the end of the treatment, the animals were 
tested at an open field and elevated plus maze task. And finally, 
blood samples were collected through a small incision on the tail 
vein, for measuring lithium plasmatic concentration.
1. Treatment
The lithium rich feed was produced by mixing conventional 
commercial chow dust with a watery lithium chloride solution of 
known concentration. After that the rat chow pellet was extruded 
and dried in an oven.
2. Open field task
After a habituation period, the exploratory behavior of all animals 
was analyzed at an 87 cm diameter wooden open field surrounded 
by a 20 cm high polyvinyl chloride wall. The apparatus’s floor was 
divided in twelve compartments by lines painted at the surface of 
a wooden disk.
In the beginning of the task, the animal was positioned in the 
center of the apparatus, and was allowed to freely explore it for 
three minutes. The number of times the animals crossed a line, 
i.e. compartments crossed, was measured as a quantification of 
horizontal locomotor activity. The vertical locomotor activity was 
assessed by measurement of the rearing frequency. The time spent in 
freezing and grooming behavior was also recorded (as an indication 
of fear and anxiety emotional states).
3. Elevated plus maze
The maze apparatus was comprised by two arms surrounded by 
30 cm high wooden walls that cross with two open arms, resulting 
in a central compartment. Both arms were 49 cm in length and 
10cm in width and were placed 50 cm above the floor.
After a five-minute task, the elevated plus maze allows to 
investigate the anxiety emotional state of rats through the 
quantification of the time spent in each arm. This apparatus 
also allows the acquisition of data from horizontal locomotor 
activity by means of quantifying the frequency of entrance in 
each compartment.
4. Plasmatic lithium level measurement
Finally, blood samples of all animals were collected through 
a small incision on tail vein, after ether anesthesia. Then, the 
plasmatic lithium levels of these blood samples were measured by 
the Crown-Ether method.
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5. Statistical analyses
Data, that fit into a normal distribution, as feed ingestion and body 
weight, were analyzed by one-factor repeated measure ANOVA. 
Data that did not fit a normal distribution (Open field, elevated plus 
maze and plasmatic lithium level) were analyzed by Kruskal-Wallis, 
followed the post-hoc test of Multiple Comparison of Mean Ranks – 
MCMR. For all statistical procedures, it was adopted a significance 
level (α) of 0.05.
Results
1. Feed consumption and body weight progression
Groups treated with both doses of LiCl-rich feed presented a 
reduced chow consumption as compared to the control group 
(p = 0.03). However, in spite of the food ingestion attenuation 
caused by lithium intake, no difference was found between the 
higher (group 0.383) and lower doses (group 0.255), as indicated 
in Figure 1.
Both groups treated with lithium rich chow showed a diminished 
body weight gain as compared with control animals (repeated 
measures ANOVA, p ≤ 0.0001 followed by Tukey-Kramer, 
p ≤ 0.05). As shown in Figure 2, lithium-treated animals gained mass 
more slowly than control rats, from the third treatment week onwards, 
resulting in a lower body weight at the end of lithium administration.
2. Open field
Animals fed with higher lithium dose chow (group 0.383) showed a 
smaller (horizontal) locomotor activity through central compartments 
of the open field as compared to the control group (Figure 3B) 
(p = 0.024, Kruskal-Wallis followed by MCMR post-hoc test). In 
spite of a 2.4 times smaller locomotion presented by group 0.383 
relative to group 0.255, this did not reach statistical significance 
(p = 0.0587). In addition, group 0.383 showed a significant 45% 
smaller rearing frequency than the control group did and a significant 
55% reduction as compared to the 0.255 group (Figure 3C). 
Moreover, group 0.383 presented a 5.2 and 3 times longer mean 
freezing duration than the control and 0.255 groups did, respectively 
(Figure 3D), but this, however, only achieved significance between 
group 0.383 and controls (p = 0.044, Kruskal-Wallis followed by 
MCMR post-hoc test). In contrast, the comparison between animals 
that received the smaller dose of LiCl and control animals produced 
only a trend (p = 0.079) in increasing the duration of freezing.
3. Elevated plus maze
While the 0.383 group presented the same total entrance (open 
plus closed arms) frequency as control animals, the 0.255 group, in 
spite of having received a smaller dose of lithium, showed a greater 
absolute number of entries than did both other groups (p = 0.008, 
Kruskal-Wallis followed by MCMR post-hoc test), as illustrated by 
Figure 4A. Moreover, animals fed with the 0.255% lithium-rich 
diet demonstrated a reduced relative entrance frequency in the 
open arms (Figure 4B), as compared to the control and 0.383 
groups (p = 0.03, Kruskal-Wallis followed by MCMR post-hoc 
test). Nevertheless, such a difference should be carefully analyzed, 
given that there was no difference among the relative time spent in 
the open arms by any experimental group (Figure 4C - Kruskal-Wallis, 
p > 0.05). Therefore, the effects induced by the treatment with the 
smaller dose of lithium chloride should be considered as a disturbance 
on animal’s behavior (thus not similar to the human mood disorder), 
rather than be classified as a parallel to human anxiety.
4. Plasmatic lithium level measurement
At the end of the six-week treatment, the plasmatic lithium level 
of the groups treated with both doses of LiCl was significantly higher 
than that of control animals (p = 0.013, Kruskal-Wallis followed by 
MCMR post-hoc test). However, in spite of having received lithium 
doses with 50% difference, groups 0.255 and 0.383 yielded the 
same lithium serum concentration (Figure 5, p = 0.73).
Discussion
1. Feed consumption and body weight progression
Animals fed with both doses of LiCl showed reduced food 
ingestion, what confirms data already collected,26 but the chow 
consumption by both lithium-treated groups was always the same, 
excluding the possibility that the same lithium serum levels could 
result from distinct amount of drug ingestion. Given that lithium 
intake can result in visceral illness,27-29 it was expected that lithium-
treated animals would present an attenuated body weight gain, as 
it is indeed confirmed in Figure 2.
2. Open field task
A central zone locomotion difference was encountered between 
control and 0.383 groups. Given that, the total locomotion of all 
groups was equal (Figure 3B, p = 0.2346), and such a divergence 
should be considered as a signal of avoidance during the exploration 
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of the apparatus, rather than altered horizontal locomotion. The 
lack of divergence in total locomotion among the groups presented 
here is in disagreement with already published studies,27,29,30 which 
demonstrated a suppressive effect of lithium salts over the horizontal 
locomotor activity. In the work of Smith,27 rats developed a lithium 
plasmatic level similar to that shown here (0.66 mMol/L ± 0.05), 
although they clearly showed a smaller locomotion after treatment 
with 1.5 mMol/L lithium for four days. It is likely that the nature of 
the lithium treatment employed here resulted in a heterogeneous 
lithium distribution through brain structures. Therefore, the animals 
evaluated in the present study showed more variability in open 
field variables analyzed, masking a possible effect of lithium on 
the evaluated parameters. While there are studies in which rats 
had received a precise amount of lithium salts by gavage,27 or 
by intraperitoneal administration,30 here, lithium was supplied 
in supplemented chow. This chow was freely available for the 
rats to ingest. Obviously the consumption rate can thus be more 
variable. Moreover, the difference in the duration of the lithium 
treatment could explain why the treatment employed here failed in 
corroborating the suppressive effect of lithium salts over horizontal 
locomotor activity, as demonstrated in the above mentioned studies. 
Such papers shown a suppressive effect of lithium upon acute 
drug administration,30 or have sustained the lithium treatment 
for a shorter time27 than performed here, suggesting a possible 
habituation to lithium’s effects during a long consumption time.
Despite the lack of a suppressive effect of lithium treatment over 
the horizontal locomotion, the group fed with the higher lithium dose 
explored the central compartment of the apparatus less often than 
the control group did. Moreover, the high-dose lithium-treated group 
also showed longer freezing time in this test than control animals. 
These behavioral consequences could be seen as suggestive of an 
anxiogenic effect of this high-dose treatment. Yet this finding was 
not confirmed by the more specific test for the assessment of anxiety 
(the elevated plus maze). Therefore, the smaller time spent in the 
central compartment of the open field test by the lithium-treated 
group under the higher dose does not unequivocally equate with 
greater anxiety, and might be more conservatively rated as an 
avoidance state
The higher dose of lithium reduced the vertical locomotor activity, 
as shown by a diminished rearing frequency of the 0.383 group. 
This suppressive action of lithium strengthens the data on the already 
known effect of lithium.27,30,31 Interestingly, the doses of lithium did 
not produce the same behavioral effect in both groups of lithium-
fed animals, in spite of the similar changes observed in the lithium 
serum levels of both groups. Therefore, lithium serum measurement 
did not allow the prediction of its levels in the brain.
3. Elevated plus maze task
The smaller open/total arms entrance rate of the 0.255 group as 
compared to control animals suggests a preference of the lithium-
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treated rats for the closed – and thus, less exposed – arms. This sign 
of anxiety was not confirmed as such given the lack of an increase 
of time spent in the closed arms (the “safer” compartment). Despite 
the well known mood stabilizing properties of lithium over emotional 
disorders, its anxiolytic or anxiogenic effects over emotional state 
of normal animals are less explored. Wood and colleagues, in 
agreement with our current findings, did not find an anxiogenic 
consequence of the treatment with lithium carbonate supplemented 
chow for 35 days in adult rats.32 On the other hand, Youngs and 
colleagues argued that adolescent rats (45-day old, rather than 
3 months of age as employed in the present study) maintained 
an anxiogenic effect of lithium for some weeks after the end of 
treatment,33 in spite of having been fed with lithium carbonate 
supplemented chow for a shorter time than here. Regardless of the 
above discrepancies or similarities with our current findings, we 
should remark that here we observed a dissimilar outcome for the 
two lithium-treated groups in the elevated plus maze despite similar 
plasmatic lithium levels. Animals that received the lower lithium 
dose (the 0.255 group) presented a greater number of entries in 
both open and closed arms as compared to others groups. Such 
a difference might be an indicative of a greater horizontal activity 
produced by the lower lithium dose in this test rather than an 
indication of anxiety. Nevertheless, this enhancement in horizontal 
locomotion must be carefully interpreted, because the same effect 
was not observed in the open field task. Moreover, this effect is 
in disagreement with already-published reports, which found 
no change in the elevated plus maze as a consequence of the 
treatment of Sprague-Dawley rats with 0.24% lithium carbonate 
supplemented chow for 35 days.32 Therefore here again, lithium 
plasmatic measurements did not seem to clearly indicate what 
would be the lithium levels in specific brain structures related to 
the analyzed behavior.
4. Plasmatic lithium concentration
Lithium is not a perfect drug due to the occurrence of short- and 
long-term side effects. However, it is the most effective drug to treat 
classical bipolar disorder, whose consequences may be even worse 
than lithium’s toxicity. Without some form of therapy, up to 20% of 
bipolar disorder patients will commit suicide,34 and lithium treatment 
reduces this rate by a factor of eight. Therefore, lithium therapeutic 
effects compensate its toxic effects making it an alternative that 
should be better understood rather than so easily discarded.
In spite of new methods that have been developed to better 
estimate a precise dose of lithium,2,3,5,17,35-39 many of these 
technologies are based in the serum level measurement. However, 
lithium does not have a uniform distribution through body 
compartments. In fact, its concentration in the brain, where it exerts 
its therapeutic actions, is higher than in the blood.6,7,24 It is very 
difficult  to estimate  CNS lithium levels, as serum and red blood 
cell concentration does not closely correlate with brain levels, with 
the coefficient for the strongest correlation (between serum and 
brain) remaining  at 0.66. 
Some authors have already pointed that lithium serum 
concentration did not satisfactorily reflect the tissue level, and 
therefore, could not predict the occurrence of toxicity.1,40 Here, 
some behavioral effects of two doses of lithium (after a six-week 
treatment) were measured at the same time that plasmatic lithium 
concentrations were obtained. According to the data presented 
above, both lithium doses resulted in similar plasmatic levels, 
although rat chows had different lithium concentrations and similar 
food consumption levels. Nevertheless, these two groups with equal 
lithium plasmatic levels, showed significantly different behavioral 
responses in some of the behavioral tests evaluated here. This 
suggests that the different lithium concentration of the ingested food 
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14.  Hashimoto R, Senatorov V, Kanai H, Leeds P, Chuang DM. Lithium 
stimulates progenitor proliferation in cultured brain neurons. 
Neuroscience. 2003;117(1):55-61.
15.  Kim JS, Chang MY, Yu IT, Kim JH, Lee SH, Lee YS, Son H. Lithium 
selectively increases neuronal differentiation of hippocampus 
neural progenitor cells both in vitro and in vivo. J Neurochem. 
2004;89(2):324-36.
16.  Linder MW, Keck PE Jr. Standards of laboratory practice: antidepressant 
drug monitoring. National Academy of Clinical Biochemistry. Clin 
Chem. 1998;44(5):1073-84.
17.  Amdisen A. Serum concentration and clinical supervision in monitoring 
of lithium treatment. Ther Drug Monit. 1980;2(1):73-83.
18.  Bartha L, Marksteiner J, Bauer G, Benke T. Persistent cognitive 
deficits associated with lithium intoxication: a neuropsychological 
case description. Cortex. 2002;38(5):743-52.
19.  Presne C, Fakhouri F, Noel LH, Stengel B, Even C, Kreis H, Mignon 
F, Grünfeld JP. Lithium-induced nephropathy: rate of progression and 
prognostic factors. Kidney Int. 2003;64(2):585-92.
20.  Livingstone C, Rampes H. Lithium: a review of its metabolic adverse 
effects. J Psychopharmacol. 2006;20(3):347-55.
21.  Frazer A, Mendels J, Brunswick D, London J, Pring M, Ramsey 
TA, Rybakowski J. Erythrocyte concentrations of the lithium ion: 
clinical correlates and mechanisms of action. Am J Psychiatry. 
1978;135(9):1065-9.
22.  Finley PR, Warner MD, Peabody CA. Clinical relevance of drug 
interactions with lithium. Clin Pharmacokinet. 1995;29(3):172-91.
23.  Levine S, Saltzman A, Katof B, Meister A, Cooper TB. Lithium 
distribution in experimental inflammation of brain and spinal cord. 
Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(6):1011-7.
24.  Ramaprasad S. Lithium spectroscopic imaging of rat brain at 
therapeutic doses. Mag Resonance Imaging. 2004;22(5):727-34.
25.  Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium 
inhibition of glycogen synthase kinase-3. Neuropsychopharmacology. 
2004;29(1):32-8.
26.  Curtis KS, Sved AF, Verbalis JG, Stricker EM. Lithium chloride-induced 
anorexia, but not conditioned taste aversions, in rats with area 
postrema lesions. Brain Res. 1994;663(1):30-7.
resulted in different brain concentrations and/or distributions, and, 
although undetectable by serum monitoring, may lead to distinct 
behavioral responses.
The experimental evidence presented here, in well-controlled 
laboratory conditions, corroborate the notion that lithium serum 
measurement does not provide an estimative of brain lithium level 
that is precise enough to predict its effects over the CNS. 
Conclusion
The measurement of serum lithium concentration, which is the 
diagnostic method currently used to monitor lithium levels in bipolar 
patients, did not detect changes in brain lithium levels, despite an 
increase of 50% in the lithium dose ingested. Behavioral tests, 
however, pointed to different cognitive performances, suggesting that 
the groups had different lithium brain concentrations or distributions 
that were sufficient to change their cognitive state. Therefore, serum 
monitoring seems to be inaccurate to ensure the safe use of lithium. 
New methods to predict the best lithium dosages for patients are 
required to allow the growing clinical use of lithium salts. 
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